Findings

What do systematic reviews say?

26 questions · 28 findings · 11 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 14.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 7.1%Moderate 9 · 32.1%High 13 · 46.4%

28 days on/off antibiotic regimen vs 28 days on/off placebo regimen

Health‐related quality of life · people with bronchiectasis

2 findings from 1 review

Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate
Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

14 days on/off antibiotic regimen vs 14 days on/off placebo regimen

Health‐related quality of life · people with bronchiectasis

2 findings from 1 review

Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High
Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atorvastatin vs placebo

Health‐related quality of life · people with asthma

The review found no eligible studies for this question.

1 finding from 1 review

Statins for asthma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vilanterol and fluticasone furoate vs placebo

Health‐related quality of life · people with asthma

Vilanterol and fluticasone furoate showed no clear difference in health‐related quality of life compared with placebo (moderate certainty).

1 finding from 1 review

Vilanterol and fluticasone furoate for asthma 2016 · Cochrane Headline outcomes only
MD 0.3
2012 participants
Moderate

RhDNase vs placebo

Health‐related quality of life · people with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Mucolytics for bronchiectasis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bromhexine vs placebo

Health‐related quality of life · people with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Mucolytics for bronchiectasis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐IL13 or anti‐IL4 agents vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 4960 participants
High

Vitamin C vs placebo

Health‐related quality of life (HRQL) · people with asthma

1 finding from 1 review

Vitamin C for asthma and exercise‐induced bronchoconstriction 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 201 participants
Low

Vitamin C vs placebo

Health‐related quality of life (HRQL) · adults and children with exercise‐induced bronchoconstriction/asthma

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin C for asthma and exercise‐induced bronchoconstriction 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cyclophosphamide vs placebo

Health‐related quality of life (HAQ‐DI) · people with connective tissue disease‐associated interstitial lung disease

1 finding from 1 review

Cyclophosphamide for connective tissue disease–associated interstitial lung disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 158 participants
Moderate

Mucolytic vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · chronic bronchitis or COPD

1 finding from 1 review

Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2721 participants
Moderate

Mepolizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 369 participants
High

Mepolizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

Benralizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2791 participants
High

Mepolizumab intravenous (IV) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 369 participants
High

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1164 participants
High

Reslizumab subcutaneous (SC) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Benralizumab subcutaneous (SC) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1541 participants
High

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1652 participants
High

Reslizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High